Drug design welcomed allopregnanolone biosynthesis as a target for novel rapidly acting anxiolytics devoid of sedation, tolerance, and withdrawal liabilities (Rupprecht et al., 2009, 2010; Schüle et al., 2011), and, in addition to low doses of SSRIs, selective ligands for the (18 kDa) translocase protein (TSPO), which increase allopregnanolone levels, may be beneficial in anxiety and PTSD (Rupprecht et al., 2009). This evidence concerns the gene TSPO and post-traumatic stress disorder.